Phase 1 Pancreatic Cancer Trial, Recruiting NCT06320990 Sponsor: University of Nebraska Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 1 Pancreatic Cancer Trial, Recruiting

NCT06320990
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 19 years of age or older
  • You have been diagnosed with a specific type of non-cancerous pancreatic cyst called a mucinous cystic neoplasm (MCN) that can be measured on a scan
  • Your doctors are not planning surgery to remove the cyst, either because of the cyst's features, your health, or your own choice
  • You are willing to use two forms of birth control throughout the study and for up to 3 months after treatment ends, if you are someone who could become pregnant or father a child (this does not apply if you are a woman aged 45 or older with no periods for 12 or more months, or if you have had your uterus and/or both ovaries surgically removed)
  • Your kidneys are functioning well enough, based on a blood test result (confirm with trial site)
  • You are willing and able to give your consent and follow the study's requirements

Who may not be able to join:

  • You have been diagnosed with invasive pancreatic cancer or a more advanced pre-cancerous change in the cyst
  • Your cyst or scan shows certain concerning features, such as a solid area, a widened pancreatic duct, yellowing of the skin (jaundice), or swollen lymph nodes
  • You are currently using, or have used in the last 5 years, tamoxifen or similar medications that block estrogen (such as clomifene, raloxifene, fulvestrant, or anastrozole)
  • You are currently using or planning to use hormone-based treatments such as estrogen, progesterone, androgens, hormone replacement therapy, or hormonal contraceptives like implants or injections (a hormonal IUD called levonorgestrel is allowed)
  • You are pregnant or breastfeeding
  • You have a known allergy or sensitivity to tamoxifen
  • You have cataracts or eye problems that are already affecting your vision
  • You currently take a blood-thinning medication called warfarin
  • You have a history of blood clots in the legs or lungs, or another condition that puts you at higher risk of blood clots
  • You have a history of stroke
  • You have been diagnosed with abnormal growth of the womb lining, or have a history of uterine or endometrial cancer
  • You have a bowel or stomach condition, or have had major stomach surgery, that could affect how your body absorbs the study medication, or you are unable to swallow pills
  • You have a serious uncontrolled illness, such as an active infection needing IV antibiotics, heart failure, unstable chest pain, or an uncontrolled heart rhythm problem
  • You have planned non-emergency surgery during the study period
  • You have taken part in another clinical trial with an experimental treatment in the last 28 days
  • The trial doctors believe, for any reason, that you would not be able to safely take part in or complete the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Kelsey Klute, MD, University of Nebraska

Phone: 402-559-1947

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
University of Nebraska
Registry
ClinicalTrials.gov
Start date
22 January 2025
Est. completion
1 November 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Feasibility, by adherence rate; Feasibility, by retention rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov